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Abstract
Objective—This study evaluated whether structural brain lesions modulate the relationship
between pathological aggression and the dopaminergic system in traumatic brain injury (TBI).
While converging evidence suggests that different areas of prefrontal cortex modulate
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dopaminergic activity, to date no evidence exists of a modulation of endogenous dopaminergic
tone by lesion localization in penetrating TBI (pTBI).
Methods—This study included 141 male Caucasian veterans who suffered penetrating pTBI
during their service in Vietnam and 29 healthy male Caucasian Vietnam veterans. Participants
were genotyped for three functional single nucleotide polymorphisms (SNPs): dopamine receptor
D1 (DRD1) rs686 and dopamine receptor D2 (DRD2) rs4648317 and catechol-o-methyltransferase
(COMT) Val158Met. Patients underwent brain CT scans and were divided into medial prefrontal
cortex, lateral prefrontal cortex, and posterior cortex lesion groups. Long-term aggression levels
were evaluated with the agitation/aggression sub-scale of the Neuropsychiatric Inventory.
Results—Our data showed that carriers of more transcriptionally active DRD1 alleles compared
to non-carriers demonstrated greater aggression levels due to medial prefrontal cortex lesions but
reduced aggression levels due to lateral prefrontal cortex lesions independently of DRD2
rs4648317 or COMT Val158Met genotypes.
Conclusions—Our results suggest that the relationship between pTBI-related aggression and the
dopaminergic system is modulated by lesion location. Potentially lesion location could represent
an easy-to-use, widely-available para-clinical marker to help in the development of an
individualized therapeutic approach to pTBI-related pathological aggression.
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Introduction and Aim
Pathological chronic aggressive behavior has been reported in up to 33% of patients with a
traumatic brain injury (TBI).1 A number of different factors, including genetic
predisposition, mono-aminergic system activity, and brain lesion location are all thought to
play a significant role in the development and maintenance of TBI-related aggression.2
Regarding the symptomatic treatment options for aggression in TBI, to date most attention
has been focused on the dopaminergic system.3
Despite the widespread use of anti-dopaminergic drugs to treat aggression4, converging
evidence suggest that the relationship between dopamine and aggression is more complex
than previously thought. In experimental models, for example, both D2 agonist and
antagonists as well as D1 partial agonists and antagonists have been shown to reduce
aggressive behaviors,5,6,7 while the classic pro-dopaminergic amphetamine has been shown
to increase, decrease, or fail to change aggressive behavior levels depending on various
factors such as context and type of aggression.8
Moreover, in humans, despite the consensus on the role of anti-psychotics to treat
aggression, pro-dopaminergic stimulants drugs have also been proposed as a possible
pharmacological treatment for aggressive behaviors in specific patient groups. In attention
deficit hyperactivity disorder (ADHD) patients, for example, stimulants have been shown to
reduce aggressive behavior by re-modulating to prefrontal cortex (PFC) dopamine levels,9
while pro-dopaminergic compounds have been proposed as a possible treatment for
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aggressive behavior in different dementing illnesses such as frontotemporal dementia
(FTD).10,11
Compared to the aforementioned clinical populations, the study of the biological basis of
aggressive behavior in penetrating TBI (pTBI) presents another confounding factor, i.e. the
presence of focal brain lesions, which could modulate the relationship between the
dopaminergic system and aggression. Indeed, transcranial magnetic stimulation experiments
showed that dorsolateral PFC inhibition reduces dopamine release in deep grey matter12
while dorsolateral PFC stimulation increases striatal dopaminergic activity.13 In animal
models, medial frontal lesions have been found to increase deep gray matter dopaminergic
activity,14 possibly through modulation of ventrotegmental area activity.
In this study, we explored the relationship between lesion location, pTBI-related aggressive
behaviors and dopaminergic tone. Based on aforementioned literature and previous studies
showing a significant role of PFC in aggressive behaviors,2 we hypothesized that PFC lesion
location significantly impacts the interaction between dopaminergic activity and aggression
in pTBI. Given the key nature of PFC territories in pTBI-related aggression, we predicted a
significant modulatory effect on the dopaminergic system/aggression interaction only by
PFC but not non-PFC damage, and potentially a regional specificity of lesion location inside
the PFC.
To test our hypotheses, we investigated in a group of Vietnam War Veterans the interaction
between long-term pathological aggression, lesion location, and inter-individual differences
in endogenous dopaminergic tone due to functional single nucleotide polymorphic (SNPs)
differences in the main components of the dopaminergic system,15,16 i.e., the dopamine
receptor D1 (DRD1), the dopamine receptor D2 (DRD2) and the dopamine-degrading
enzyme Catechol-O-methyltransferase (COMT).
We decided to focus on these components of the dopaminergic system as DRD1 and DRD2
represent the prototypical members of the two groups of dopamine receptors (i.e., DRD1-
like and the DRD2-like families),15 while COMT is thought to represent the major
dopamine-degrading enzyme in the synaptic cleft.16 Evaluation of functional SNPs has been
shown to be a useful tool to study the relationship between aggressive behaviors and mono-
aminergic systems, both in healthy subjects and neuropsychiatric conditions15,16 as well as a
proxy-marker of baseline dopaminergic tone in pharmacological challenges studies.17
Methods
Patient selection
Patients were drawn from Phase 3 of the Vietnam Head Injury Study (VHIS)18 conducted
between 2003 and 2006 (36–39 years post-injury) at the Bethesda National Naval Medical
Center, Bethesda, MD, USA. Pre-injury characteristics and follow-up data of the
participants (n=189) were available from military and Veterans Administration records.
Inclusion criteria were the availability of SNP data and a negative history for treatments
with drugs acting on the dopaminergic or serotoninergic system and for alcohol dependence.
Eight subjects were removed due to the lack of SNP data, nine subjects due to alcohol
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dependence, while two subjects were excluded on the basis of previous pharmacological
treatments. We thus included 141 Caucasian male veterans who suffered pTBI during their
service in Vietnam and 29 healthy Caucasians male Vietnam veterans. Each subject
underwent neurologic and psychiatric examinations and pTBI subjects received a non-
contrast brain CT scan.
Standard protocol approvals, registrations, and patient consents
All subjects gave informed written consent before enrollment in the study. The National
Naval Medical Center and the NIH Institutional Review Boards approved all the study
procedures.
Behavioral evaluation
Long-term aggression levels were evaluated with the agitation/aggression sub-scale of the
Neuropsychiatric Inventory (NPI-a),19 completed by the patients’ caregivers. The NPI-a is
based on a semi-structured interview and grades aggressive behaviors from 0 to 12 with
higher values indicating more severe levels of aggression. The NPI-a has been used in
clinical studies on aggression in brain injury2 and other neurological conditions.19
Moreover, we also used the total NPI (NPI-t) score as a global index of psychopathology.
Lastly, we evaluated early psychological trauma by administering the Early Trauma
Inventory (ETI), a validated 56-item interview designed for the assessment of childhood
negative experiences.20
Computed tomography (CT) scans
Axial non-contrast CT scans were acquired on a GE Medical Systems Light Speed Plus CT-
scanner in helical mode as described elsewhere.18 Briefly, images were reconstructed with
an in-plane voxel size of 0.4 mm × 0.4 mm, overlapping slice thickness of 2.5 mm and a 1
mm slice interval. Lesion location and volume were determined from CT images by manual
tracing using the Analysis of Brain Lesion (ABLe)22 software implemented in MEDx v3.44
(Medical Numerics) with enhancements to support the Automated Anatomical Labeling
(AAL) atlas.22 A trained neuropsychiatrist (V.R.) performed the tracings, which were then
reviewed by an experienced observer (J.G.) who was blind to the results of the clinical
evaluations. The skull and scalp were then removed from the CT images; each volume was
spatially normalized to a de-skulled CT scan, which was previously spatially normalized to
the T1 MNI brain (standard of the International Consortium for Brain Mapping). The ABLe
software was used to exclude the manually delineated lesion from the spatial normalization
process to improve registration accuracy. Spatial normalization was performed using an
automated image registration algorithm using a 12-parameter affine model. The medial PFC
(mPFC) region of interest was defined as those areas of the PFC medial to x= −20 and to x=
20 in the MNI space as previously described.23 Subjects with a PFC lesion encompassing or
partially encompassing the mPFC were included in the mPFC group, while all other subjects
with PFC lesions were included in the lateral PFC (lPFC) group. Subjects with non-PFC
lesions were included in the non-PFC groups.
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Differences in lesion localization among the three groups are reported in Figure 1 using
lesion subtraction maps that have been previously used in pTBI research to characterize
differences in lesion localization among groups.2
Genetic analysis
From a published SNP array24 we selected the following functional SNPs: DRD1 rs686 (A-
to-G), DRD2 rs4648317 (C-to-T), COMT Val158Met rs4680 (G-to-A). Rs686 is a
functional SNP located in the promoter region of the DRD1 gene; its A allele is linked with
increased transcriptional activity compared to the G allele.25 Rs4274224 is located in the
first intronic region of the DRD2 gene; the minor allele has been linked with reduced D2
expression in healthy controls compared to the Major allele,26 moreover, this SNP has been
shown to impact behavioral inhibition.27 COMT Val158Met rs4680 is a widely studied SNP
in neuropsychiatry and the Val allele is thought to be linked with a reduced efficiency in the
degradation of dopamine.16 Lastly, we decided to control for possible differences among
subjects for the monoamine oxidase A (MAO-A) genotype, one of the genes more
commonly linked to pathological aggression.2,28 While the main role of the MAO-A is
serotonin metabolism rather than dopamine, we decided to include it as a confounding factor
since the common variable number tandem repeat (VNTR) polymorphism is known to
impact on aggression levels in the general population.28 VNTR MAO-A polymorphisms is
thought to modulate MAO-A activity with the 3.5 and 4 repeats linked with MAO-A high-
activity and 2, 3, and 5 repeats linked with low MAO-A activity. Genotyping for the those
SNPs was performed as described elsewhere.2,18,24
Statistical analysis
Statistical threshold was set at 0.05 (two-tailed) for all first level analyses. For each of our
target SNPs (DRD1 rs686, DRD2 rs4648317 and COMT Val158Met rs4680) a mixed 2 × 4
analysis of covariance (ANCOVA) on NPI-a (and NPI-t as a control measure) was
performed with Genotype (Major allele/-, Minor allele/Minor allele) and Group (mPFC,
lPFC, non-PFC, control) as between-subjects factors and the other target genes as covariates.
Based on our results (see below) we also performed a 2 × 4 ANCOVA on NPI-a scores (and
NPI-t scores) with DRD1 Genotype and Group as between-subjects factors and DRD2,
COMT and MAO VNTR genotype as covariates. Follow-up independent t-tests (Bonferroni
corrected for multiple comparisons) were performed for the rs686 genotypes within each
lesion group.
Results
Group characteristics
All four groups did not present with significant differences in pre-injury intelligence
(F(3,165)=1.2, p=0.31), early life negative experiences (F(3,165)=0.7, p=0.55), education level
(F(3,165)=0.8, p=0.50), and age (F(3,165)=0.4, p=0.75) and the lesion groups were matched on
percentage of brain tissue loss due to pTBI (F(2,137)=0.9, p=0.41) (Tab. 1). Lesion
subtraction maps are reported in Figure 1. Frequency distributions for the genotyping results
were as follows: DRD1: 97 A/- vs. 73 G/G subjects; DRD2: 117 C/- vs. C/- subjects vs. 53
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T/T; COMT: 107 Val/- vs. 63 Met/Met subjects; MAO-A: 59 low-activity vs 111 high-
activity subjects.
DRD1
The ANCOVA on NPI-a revealed a significant interaction effect for DRD1 Genotype-x-
Group (F(3,159)=9.5, p=0.001), but no significant main effects were found for DRD1
Genotype (F(1,159)=0.4, p=0.58) and Group (F(3,159)=1.2, p=0.35) and no covariate effect for
COMT (F(1,159)=0.45, p=0.55), DRD2 (F(1,159)=0.60, p=0.4) or MAO-A (F(1,159)=0.35,
p=0.35). Planned follow-up analyses showed that DRD1 A/- carriers had higher NPI-a
scores than G/G carriers in the mPFC group (t=2.99, p=0.004; Cohen’s d= 1.9), whereas
DRD1 A/- carriers had lower NPI-a scores than G/G carriers in the lPFC group (t=3.82,
p=0.002; Cohen’s d=1.89 (Figure 2). No significant differences were found between
genotypes in the non-PFC (t=0.92, p=0.36) and control (t=0.72, p=0.48) groups. The
ANCOVA on NPI-t revealed no significant main effects (DRD1 Genotype: F(1,159)=1.5,
p=0.25; Group: F(3,159)=0.85, p=0.38), interaction effect (F(3,159)=1.1, p=0.37), and COMT,
DRD2 or MAO-A covariate effects.
DRD2
The DRD2 x Group ANCOVA performed on NPI-a scores revealed no significant main
effects (DRD2 genotype: F(1,159)=1.7, p=0.52; Group: F(3,159)=0.5, p=0.80), interaction
effect (F(3,159)=0.15, p=0.92), and DRD1, COMT and MAO-A covariate effects.
COMT
The COMT genotype x Group ANCOVA performed on NPI-a scores revealed no significant
main effects (COMT genotype: F(1,159)=0.7, p=0.40; Group: F(3,159)=0.2, p=0.89),
interaction effect (F(3,159)=0.15, p=0.92), and DRD1, DRD2 and MAO-A covariate effects.
Discussion
In this study we studied the relationship between TBI-related aggression and the
dopaminergic system and its modulation by lesion location. Our results revealed a
significant interaction between aggressive behavior and the DRD1 rs686 SNP depending
upon PFC lesion location. We showed that carriers of the major and more transcriptionally
active allele of DRD1 were more aggressive compared to the minor allele homozygotes in
the mPFC group, while conversely DRD1 major allele carriers were less aggressive than
minor allele homozygotes in the lPFC group.
Moreover, we did not observe any significant interactions between lesion location and
genotype our DRD2 or COMT functional SNPs, thus suggesting a possible specificity of
this effect to DRD1 receptors. Lastly, no genotype effects were observed in the non-PFC
and control groups or when taking into account the global index of psychopathology.
We propose that our observation of high aggression levels in two specific sub-sets of pTBI
patients —subjects with mPFC lesions and more expressed DRD1 receptors and subjects
with lPFC lesions and less expressed DRD1 receptors— can be explained by analogy to the
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known relationship between impaired cognitive performance and excessively high or low-
levels of dopamine (i.e., the observed “U-curve” relationship between cognitive
performance and dopaminergic tone).29
While the “U-shaped curve” relationship between function and dopamine levels was first
observed at the neural level, recent years have seen its generalization to the behavioral,
whole-organism setting. In rats, for example, both D1 agonists and antagonists have been
shown to impair working memory performance in a dose-dependent function, leading to a
U-shaped curve like relationship (i.e. rats presented an equally pathological performance
both during excessive inhibition and excessive stimulation of the D1 receptors).30 Moreover,
in line with the proposed U-shaped curve relationship between dopamine tone and
performance a DRD2 agonist —cabergoline— increased neural reward responses during a
feedback-based reversal learning fMRI task in healthy subjects with low DRD2 receptor
density due to the A1+ Taq1A SNP, while it reduced reward responses in those subjects
with higher DRD2 receptor density due to the A- Taq1A SNP.17 Lastly a dopamine agonist,
bromocriptine, has been shown to increase cognitive performance in healthy subjects with
lower baseline dopamine synthesis —as quantified with fluoro-L-m-tyrosine PET scans—
but showed an opposite effect (i.e. a performance reduction) is subjects with higher baseline
dopaminergic tone.31
Our findings suggest that subjects with lPFC lesions and less expressed DRD1 represent the
other extreme of the proposed “U-shaped curve” relationship between dopaminergic tone
and aggression (i.e., association of high levels of aggression with reduced D1 signaling).
This proposal is in line with the observed reduction of deep brain dopaminergic activity in
lPFC virtual-lesion studies based on theta-burst TMS13 and an increased striatal
dopaminergic tone after lPFC activation.14
Thus, the combination of reduced dopaminergic activity with low DRD1 expression could
lead to low D1 tone in different sub-cortical areas linked with aggression, such as the
nucleus accumbens (NA). According to pharmaco-fMRI studies, low D1 activity is linked
with a blunted NA responses to environmental stimuli.32 A similar blunted NA response to
environmental stimuli has been shown in subjects with ADHD and it has been correlated
with the extent of externalizing symptoms, which include aggressive conduct.33
Interestingly, pro-dopaminergic stimulants are widely used to control externalizing
aggressive behaviors in ADHD9 as well as in some experimental models of aggression.34
Lastly, a relationship between NA neurodegeneration and disinhibited behavior has been
shown in FTD in which pro-dopaminergic stimulants are used to treat aggression.35
Our findings also indicate that subjects with mPFC lesions and more expressed DRD1
represent the “high dopamine” end of the proposed “U-shaped curve”. The mPFC territories
are richly inter-connected with the ventrotegmental area (the origin of the mesolimbic
dopaminergic pathway to the NA) suggesting a modulatory effect of mPFC on the
dopaminergic system,36 as shown in animal lesion models in which the structural lesion of
medial PFC territories was linked with an increase in NA dopaminergic activity.15 These
observations are in line with the observed activation by mPFC projections of inhibitory
GABA-ergic inter-neurons in the dopaminergic mesolimbic pathway36 as well as with the
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reported inverse correlation between mPFC and NA activity during immediate reward
evaluation in impulsive subjects.37 Given the relationship between D1 signaling and NA
activity, the presence of mPFC lesions in subjects with highly expressed DRD1 could lead to
an excessively active NA, especially in behaviorally relevant impulsive decision making
settings, and possibly to heightened aggressive behaviors.38
We propose that our finding of high aggression levels in pTBI subjects with mPFC lesions
and more expressed DRD1 and in subjects with lPFC lesions and less expressed DRD1
supports a U-shaped modulation of the function of the mesolimbic dopaminergic system.
Coincidentally, in a recent meta-analysis of striatal activation during reward anticipation
tasks, a similar U-shaped curve paradigm has been proposed to link the reduced reward
responsiveness of mesolimbic striatal structures observed in subjects with extremely high or
extremely low impulsivity observed in ADHD and healthy control group.39 Our findings
have a potential translational application in the pharmacological treatment of behavioral
disturbances in pTBI patients.40 Lesion location could represent a low-cost, easy-to-use,
para-clinical marker to help, among other factors, in the development of individualized
treatment protocols.
Indeed, our findings seem to suggest that in subjects with isolated lPFC lesions D1-agonists
could represent the treatment of choice for aggressive behaviors, while the compounds in
this class should be avoided in subjects with isolated mPFC lesions. Albeit indirectly,
moreover, our data also advise prudence in the use of D1-active drugs in subjects with
mixed mPFC/lPFC, even if our study did not directly investigate this patient group.
However, while this proof-of-concept study suggests the importance of a personalized
approach to aggression treatment in pTBI, future studies are needed to explore its relevance
in day-to-day clinical care.
Interestingly (but unexpectedly), given the widespread use of D2-antagonists to treat
behavioral disturbances in pTBI,41 we did not find any effect of the DRD2 SNP on
aggression in our target populations. We argue that this observation, while it needs to be
interpreted with caution, is in line with the growing evidence of the difficulties of
generalization of findings from general psychiatry to neuropsychiatry. Indeed, different
studies showed that chronic reduction of D2 tone using DRD2 inhibitors after TBIs
increases the risk of stable cognitive deficits42,43 which, given the relationship between
cognitive deficits and behavioral disturbances in pTBI, could counter the potentially positive
effect of D2 inhibition on aggressive behaviors in this population.
One of the key aspects of our study is the composition of our patient group. Our
experimental group is highly homogeneous regarding pTBI (all subjects suffered combat-
related pTBI during their service in Vietnam), their demographic characteristics (all subjects
suffered pTBI during their early adulthood) and their pre-injury cognitive level. Moreover,
all subjects were matched for their early negative experience burden and their exposure to
aggressive environments (i.e., all of them were exposed to infantry warfare and suffered a
major injury). While this homogeneity allowed us to control for possible confounding
factors (e.g., pre-injury characteristics, TBI dynamics and exposure to significant aggressive
behaviors), it also represents the main limitation of this study, prompting the need to also
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evaluate our findings in non-military heterogeneous populations. Another limitation of this
study is the lack of anatomical information on pTBI-related white matter damage since
retained metal fragments in the brain preclude high resolution structural MRI studies.
Moreover, in this study we focused on DR1 and DR2 as they represent the prototypical
members of the two families of dopamine receptors (i.e. the DRD1-like and the DRD2-like
families).15 Future studies, however, are warranted to explore the role of other dopaminergic
receptors in behavioral disturbances in pTBI, especially taking into account the differences
in the anatomical localization of the different receptors. DRD4, for example, seems to be of
particular interest as it is widely expressed in the PFC44 and been associated with inter-
individual differences in externalizing behaviors45 as well as with resilience after negative
life experiences.46
The longitudinal aspect of our study allowed us to evaluate the behavioral consequences of
pTBI across the patients’ lifetime, which are a major determinant of quality of life levels
both for our patients and their carers. Furthermore, the length of our follow-up suggests
caution in the interpretation of our data, especially regarding their generalizability to the
acute and sub-acute settings.
Conclusions
Our results suggest that pTBI modulates the relationship between pTBI-related aggression
and the dopaminergic system in a lesion-location dependent way; potentially lesion location
could help in the development of individualized therapies for treatment-resistant aggression,
for example suggesting prudence in the use of D1-antagonists in subjects with lPFC lesions
or of D1-agonists in subjects with mPFC damage. Pharmacological studies are warranted to
explore the translational relevance of our findings.
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Clinical implication points
• One of the un-met needs in the current approach to neuropsychiatric
disturbances after penetrating traumatic brain injury is the lack of para-clinical
indexes to guide individualized therapy.
• Here we showed that lesion localization modulates the relationship between
aggression and the dopaminergic system, which we propose can be
conceptualized as an “U” curve. Our observations seem to confirm animal and
basic human neurophysiology studies which seem to suggest that medial
prefrontal lesions and lateral prefrontal lesions might respectively increase and
decrease striatal dopaminergic tone.
• According to our data, lPFC lesions seem to be associated with more aggressive
behaviors in subjects with a lower baseline transcriptional activity of the DRD1
gene, while mPFC lesions seem to be associated with aggressive behaviors in
subjects with a higher baseline transcriptional activity of the DRD1 gene.
Pardini et al. Page 13
CNS Spectr. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Subtraction lesions maps for the mPFC group (red), lPFC group (green) and non-PFC group
(blue). For each group, the subtraction lesion map shows those brain areas that were more
lesioned in one group compared to the other groups. Note that each subject was only
included in one group.
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Figure 2.
NPI-a scores (mean ± s.e.m.) for the lesion groups divided according to the functional SNP
DRD1 rs686. *Indicates a significant difference between the two genotype groups at p<0.05
(Bonferroni correction).
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